Aragen Life Sciences Prepares for Significant IPO Launch
Aragen Life Sciences Limited is gearing up for a significant initial public offering (IPO) of equity shares. This IPO includes a fresh issue amounting to ₹800 crore, alongside an offer for sale involving up to 27,329,192 equity shares from selling shareholders.
Cyril Amarchand Mangaldas Role: The renowned law firm Cyril Amarchand Mangaldas is providing legal counsel to Aragen Life Sciences during this IPO process. The team spearheading this transaction consists of Senior Partner Yash J. Ashar and Partner Tanvi Kini, with support from Senior Associate Surya Rajkumar. Additional assistance is provided by Associates Tejaswi Sade, Mohammed Khadri, Maria Palamattom, and Akshita Dhawan.
TT&A’s Involvement: TT&A is advising the selling shareholders, specifically Leo Investment Holdings Pte. Ltd. and Quadria Capital India Fund III, both affiliates of Quadria. This transaction is led by Partner Abhinav Kumar and Senior Associate Indira Satish.
Trilegal’s Advisory: The legal advisory for the Book Running Lead Managers, which include Axis Capital, Citigroup Global, Goldman Sachs, and JM Financial, is being handled by Trilegal. The team is led by Partners Bhakta Patnaik and Albin Thomas, with contributions from Counsel Bhargavi Mahajan and Associates Janhavi Shah, Snehal Kaushal, Tushar Chitlangia, Mohak Agarwal, and Harshali Srivastava.
Aragen Life Sciences, recognized as the largest Contract Research, Development and Manufacturing Organization (CRDMO) among its Indian peers in terms of the number of solutions it offers within the drug development value chain, is a leading platform in India. The company provides comprehensive solutions across the drug development lifecycle for both small molecules and biologics, as detailed in the F&S Report dated March 31, 2026.
